Swiss antibody-drug conjugate specialist ADC Therapeutics (NYSE: ADCT) has submitted to the US regulator for approval to market loncastuximab tesirine as a third-line option.
ADC wants to offer the treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and has submitted data from the Phase II LOTIS 2 study.
The results, which were presented at the virtual 25th Congress of the European Hematology Association, showed an overall response rate of 48.3% and a complete response rate of 24.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze